GT199900111A - (3s) tetrahidro-3-furanil (1s,2r)-3-[[(4-aminofenil) sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamatode calcio. - Google Patents
(3s) tetrahidro-3-furanil (1s,2r)-3-[[(4-aminofenil) sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamatode calcio.Info
- Publication number
- GT199900111A GT199900111A GT199900111A GT199900111A GT199900111A GT 199900111 A GT199900111 A GT 199900111A GT 199900111 A GT199900111 A GT 199900111A GT 199900111 A GT199900111 A GT 199900111A GT 199900111 A GT199900111 A GT 199900111A
- Authority
- GT
- Guatemala
- Prior art keywords
- viral
- propilcarbamatode
- fosfonooxi
- aminofenil
- isobutil
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title 1
- 229910052791 calcium Inorganic materials 0.000 title 1
- 239000011575 calcium Substances 0.000 title 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 title 1
- 102000014961 Protein Precursors Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 108010078762 Protein Precursors Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000006514 viral protein processing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÒN CONCIERNE AL COMPUESTO MENCIONADO CUYA ESTRUCTURA APARECE ABAJO COMO FÒRMULA (I) EN CUYO PROCESO SE TRATA EL COMPUESTO DE FÒRMULA (II) CON UN AGENTE FOSFORILANTE, COMPOSICIONES FARMACÈUTICAS QUE LO CONTIENEN, SU USO EN EL TRATAMIENTO DE INFECCIONES RETROVIRALES, Y PROCESOS PARA SU PREPARACIÒN. PROTEASAS DE VIRUS CODIFICADO, QUE SON ESENCIALES PARA RÈPLICA VIRAL, SE REQUIEREN PARA EL PROCESAMIENTO DE PRECURSORES DE PROTEÌNAS VIRALES. LA INTERFERENCIA CON EL PROCESAMIENTO DE PRECURSORES DE PROTEÌNAS INHIBE LA FORMACIÒN DE VIRIONES INFECCIOSOS. POR CONSIGUIENTE, INHIBIDORES DE PROTEASAS VIRALES PUEDEN SER USADOS PARA PREVENIR O TRATAR INFECCIONES VIRALES CRÒNICAS O AGUDAS. UNA PARTICULARIDAD DE LA INVENCIÒN ES SU USO EN FORMA CRISTALINA QUE PUEDE SER CARACTERIZADO POR PATRON DE DIFRACCIÒN DE RAYOS X.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815567.4A GB9815567D0 (en) | 1998-07-18 | 1998-07-18 | Antiviral compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT199900111A true GT199900111A (es) | 2001-01-05 |
Family
ID=10835689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT199900111A GT199900111A (es) | 1998-07-18 | 1999-07-15 | (3s) tetrahidro-3-furanil (1s,2r)-3-[[(4-aminofenil) sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamatode calcio. |
Country Status (47)
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9914821D0 (en) * | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
| ES2307533T3 (es) * | 1999-10-06 | 2008-12-01 | Tibotec Pharmaceuticals Ltd. | Hexahidrofuro(2,3)furan-3-il-n-(3-((1,3-benzodioxol-5-ilsulfonil)(is obuti)amino)-1-bencil-2-hidroxipropil carbamato como inhibidor de la proteasa retroviral. |
| PE20010635A1 (es) * | 1999-10-08 | 2001-08-15 | Smithkline Beecham Corp | Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas |
| DK1560584T3 (da) * | 2001-04-06 | 2009-05-18 | Affinium Pharm Inc | Fab I inhibitorer |
| CN101041669A (zh) * | 2002-04-26 | 2007-09-26 | 吉里德科学公司 | 非核苷逆转录酶抑制剂 |
| DK1575951T3 (da) * | 2002-12-06 | 2014-09-15 | Debiopharm Int Sa | Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi |
| CA2519429C (en) | 2003-03-17 | 2013-08-06 | Affinium Pharmaceuticals, Inc. | Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics |
| US7429565B2 (en) | 2003-04-25 | 2008-09-30 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
| US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| US7300924B2 (en) | 2003-04-25 | 2007-11-27 | Gilead Sciences, Inc. | Anti-infective phosphonate analogs |
| EP1620109A2 (en) | 2003-04-25 | 2006-02-01 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
| US20080234288A1 (en) * | 2003-09-30 | 2008-09-25 | Kenneth Alan Simmen | Hcv Inhibiting Sulfonamides |
| WO2005044308A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
| WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
| US7273717B2 (en) | 2003-10-24 | 2007-09-25 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B |
| MXPA06006899A (es) | 2003-12-22 | 2006-09-04 | Gilead Sciences Inc | Derivados de carbovir y abacavir 4'-sustituidos asi como compuestos relacionados con actividad antiviral de virus de inmunodeficiencia humana y virus de la hepatitis c. |
| KR101299399B1 (ko) | 2004-06-04 | 2013-08-22 | 아피늄 파마슈티컬스, 인크. | 치료제, 및 그의 제조 및 사용 방법 |
| HRP20070078A2 (hr) | 2004-07-27 | 2007-05-31 | Gilead Sciences | Fosfonatni analozi spojeva koji inhibiraju hiv |
| JP5116479B2 (ja) | 2004-11-26 | 2013-01-09 | ユーシーエル ビジネス ピーエルシー | オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物 |
| US20090156578A1 (en) * | 2005-12-05 | 2009-06-18 | PAULS Henry | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents |
| WO2008009122A1 (en) | 2006-07-20 | 2008-01-24 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab i inhibitors |
| EP2125802A4 (en) * | 2007-02-16 | 2014-08-20 | Debiopharm Int Sa | SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS |
| CN102816111B (zh) | 2007-03-12 | 2014-08-06 | 尼克塔治疗公司 | 低聚物-蛋白酶抑制剂偶联物 |
| EP2262538B1 (en) * | 2008-03-12 | 2014-12-10 | Nektar Therapeutics | Oligomer-amino acid conjugate |
| PT2307435E (pt) | 2008-07-08 | 2012-09-19 | Gilead Sciences Inc | Sais de compostos inibidores de vih |
| CA2998344C (en) * | 2009-04-03 | 2020-06-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| US20120135965A1 (en) * | 2009-05-20 | 2012-05-31 | Ranbaxy Laboratories Limited | Amorphous fosamprenavir calcium |
| US20120157526A1 (en) | 2009-06-08 | 2012-06-21 | Ucl Business Plc | Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate |
| EP2440249A2 (en) | 2009-06-12 | 2012-04-18 | Nektar Therapeutics | Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety |
| WO2011001383A1 (en) | 2009-06-30 | 2011-01-06 | Ranbaxy Laboratories Limited | Crystalline form of fosamprenavir calcium |
| AU2010296846B2 (en) * | 2009-09-16 | 2013-11-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of fosamprenavir calcium |
| EP2507250A1 (en) * | 2010-01-07 | 2012-10-10 | Pliva Hrvastka D.O.O. | Solid state forms of fosamprenavir calcium salt and process for preparation thereof |
| SMT201800290T1 (it) | 2010-01-27 | 2018-07-17 | Viiv Healthcare Co | Terapia antivirale |
| US20110224443A1 (en) * | 2010-03-15 | 2011-09-15 | Venkata Naga Brahmeshwara Rao Mandava | Preparation of fosamprenavir calcium |
| WO2011114212A1 (en) | 2010-03-19 | 2011-09-22 | Lupin Limited | Ammonium, calcium and tris salts of fosamprenavir |
| US20130211108A1 (en) | 2010-06-18 | 2013-08-15 | Mylan Laboratories Ltd | Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts |
| US8877947B2 (en) | 2010-09-10 | 2014-11-04 | Lupin Limited | Process for preparation of substantially pure fosamprenavir calcium and its intermediates |
| JP6087284B2 (ja) | 2010-10-06 | 2017-03-01 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンフェニルアセテートを製造するための方法 |
| CN102453053B (zh) * | 2010-10-29 | 2014-11-26 | 浙江九洲药业股份有限公司 | 一种福沙那韦钙晶体及其制备方法 |
| CN102453054B (zh) * | 2010-10-29 | 2015-06-10 | 浙江九洲药业股份有限公司 | 一种福沙那韦衍生物的制备方法及相关中间体 |
| WO2012085625A1 (en) | 2010-12-21 | 2012-06-28 | Lupin Limited | Process for the preparation of fosamprenavir calcium and intermediate used in its preparation |
| JP2014513044A (ja) * | 2011-02-10 | 2014-05-29 | マイラン ラボラトリーズ リミテッド | ホスアンプレナビルカルシウム結晶およびその調製方法 |
| WO2013011485A1 (en) | 2011-07-20 | 2013-01-24 | Ranbaxy Laboratories Limited | Process for the preparation of sulfonamides useful as retroviral protease inhibitors |
| US9233943B2 (en) | 2012-01-10 | 2016-01-12 | Council Of Scientific & Industrial Research | Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir |
| BR122021020778B1 (pt) | 2012-06-19 | 2022-07-12 | Debiopharm International Sa | Derivados de pró-fármaco de (e)-n-metil-n-((3-metilbenzofuran-2-il) metil)-3-(7-oxo-5,6,7,8-tetraidro- 1, 8- naftirindin-3-il) acrilamida |
| CN107206021B (zh) | 2014-11-24 | 2021-09-03 | Ucl商业有限公司 | 使用降氨疗法治疗与肝星状细胞激活相关的疾病 |
| US10835506B2 (en) | 2015-08-18 | 2020-11-17 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| SI3419628T1 (sl) | 2016-02-26 | 2021-03-31 | Debiopharm International Sa | Zdravilo za zdravljenje infekcij diabetičnega stopala |
| JP7126520B2 (ja) | 2017-05-11 | 2022-08-26 | オセラ セラピューティクス， インコーポレイテッド | Ｌ－オルニチンフェニルアセテートを製造する方法 |
| WO2019027920A1 (en) | 2017-08-01 | 2019-02-07 | Gilead Sciences, Inc. | CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS |
| PH12021551922A1 (en) | 2019-02-14 | 2022-05-23 | Debiopharm Int Sa | Afabicin formulation, method for making the same |
| UA129222C2 (uk) | 2019-06-14 | 2025-02-12 | Дебіофарм Інтернешнл С.А. | Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2698826A (en) * | 1951-02-13 | 1955-01-04 | Merco Centrifugal Co | Alcohol manufacturing process |
| US3437267A (en) * | 1966-03-24 | 1969-04-08 | Alfa Laval Ab | Centrifuge |
| JPH0244315B2 (ja) * | 1982-06-14 | 1990-10-03 | Microbial Chem Res Found | Supagarinn155hosufueetooyobisonoseizoho |
| US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
| UA49803C2 (uk) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
| AU2010299A (en) * | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
| US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| HUP0101598A3 (en) * | 1997-12-24 | 2002-08-28 | Vertex Pharmaceuticals Inc Cam | Prodrugs of aspartyl protease inhibitors and medicaments containing them |
| GB9812189D0 (en) * | 1998-06-05 | 1998-08-05 | Glaxo Group Ltd | Methods and compositions for increasing penetration of HIV protease inhibitors |
| AU6329599A (en) * | 1998-09-28 | 2000-04-17 | Glaxo Group Limited | Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester |
| CA2346131C (en) * | 1998-11-04 | 2013-01-15 | Pharmacia & Upjohn Company | Method for improving the pharmacokinetics of tipranavir |
| CZ20002364A3 (cs) * | 1998-12-23 | 2000-11-15 | Vertex Pharmaceuticals Incorporated | Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje |
| GB9914821D0 (en) * | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
| US6642237B1 (en) * | 1999-11-24 | 2003-11-04 | Merck & Co., Inc. | Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof |
-
1998
- 1998-07-18 GB GBGB9815567.4A patent/GB9815567D0/en not_active Ceased
-
1999
- 1999-07-14 GC GCP1999203 patent/GC0000105A/xx active
- 1999-07-14 AR ARP990103446A patent/AR019388A1/es not_active Application Discontinuation
- 1999-07-14 DZ DZ990145A patent/DZ2845A1/xx active
- 1999-07-15 OA OA1200100016A patent/OA11706A/fr unknown
- 1999-07-15 PL PL99345620A patent/PL195736B1/pl unknown
- 1999-07-15 EP EP02013136A patent/EP1240903A3/en not_active Withdrawn
- 1999-07-15 EE EEP200100038A patent/EE200100038A/xx unknown
- 1999-07-15 ID IDW20010145A patent/ID28070A/id unknown
- 1999-07-15 AU AU50379/99A patent/AU766056B2/en not_active Expired
- 1999-07-15 PT PT99934698T patent/PT1098898E/pt unknown
- 1999-07-15 BR BRPI9912156A patent/BRPI9912156B8/pt not_active IP Right Cessation
- 1999-07-15 AT AT99934698T patent/ATE229964T1/de active
- 1999-07-15 JP JP2000560139A patent/JP3437553B2/ja not_active Expired - Lifetime
- 1999-07-15 PE PE1999000714A patent/PE20000869A1/es not_active Application Discontinuation
- 1999-07-15 EP EP99934698A patent/EP1098898B1/en not_active Expired - Lifetime
- 1999-07-15 CN CNB998108383A patent/CN1188422C/zh not_active Expired - Lifetime
- 1999-07-15 ES ES99934698T patent/ES2189450T3/es not_active Expired - Lifetime
- 1999-07-15 MA MA25684A patent/MA26660A1/fr unknown
- 1999-07-15 GT GT199900111A patent/GT199900111A/es unknown
- 1999-07-15 WO PCT/EP1999/004991 patent/WO2000004033A1/en not_active Ceased
- 1999-07-15 TR TR2001/00111T patent/TR200100111T2/xx unknown
- 1999-07-15 MY MYPI99002983A patent/MY122323A/en unknown
- 1999-07-15 DK DK99934698T patent/DK1098898T3/da active
- 1999-07-15 DE DE69904600T patent/DE69904600T2/de not_active Expired - Lifetime
- 1999-07-15 TN TNTNSN99145A patent/TNSN99145A1/fr unknown
- 1999-07-15 HR HR20010046A patent/HRP20010046A2/hr not_active Application Discontinuation
- 1999-07-15 HU HU0103432A patent/HU229700B1/hu unknown
- 1999-07-15 CA CA2337857A patent/CA2337857C/en not_active Expired - Lifetime
- 1999-07-15 AP APAP/P/2001/002039A patent/AP2001002039A0/en unknown
- 1999-07-15 SK SK76-2001A patent/SK285311B6/sk not_active IP Right Cessation
- 1999-07-15 US US09/744,051 patent/US6514953B1/en not_active Expired - Lifetime
- 1999-07-15 SV SV1999000096A patent/SV1999000096A/es not_active Application Discontinuation
- 1999-07-15 EA EA200100053A patent/EA003191B1/ru not_active IP Right Cessation
- 1999-07-15 JO JO19992114A patent/JO2114B1/en active
- 1999-07-15 KR KR1020017000740A patent/KR100694721B1/ko not_active Expired - Lifetime
- 1999-07-15 YU YU3401A patent/YU3401A/sh unknown
- 1999-07-15 CO CO99044882A patent/CO5090836A1/es unknown
- 1999-07-15 CZ CZ20010219A patent/CZ300447B6/cs not_active IP Right Cessation
- 1999-07-15 GE GEAP19995716A patent/GEP20033030B/en unknown
- 1999-07-15 IL IL14082499A patent/IL140824A/en not_active IP Right Cessation
- 1999-07-15 NZ NZ509291A patent/NZ509291A/en not_active IP Right Cessation
- 1999-07-16 PA PA19998477801A patent/PA8477801A1/es unknown
- 1999-08-06 TW TW088113428A patent/TWI245770B/zh not_active IP Right Cessation
-
2001
- 2001-01-12 IS IS5808A patent/IS5808A/is unknown
- 2001-01-15 ZA ZA200100417A patent/ZA200100417B/en unknown
- 2001-01-17 NO NO20010282A patent/NO329676B1/no not_active IP Right Cessation
- 2001-02-14 BG BG105253A patent/BG105253A/xx unknown
-
2002
- 2002-11-25 US US10/303,213 patent/US20030100537A1/en not_active Abandoned
- 2002-11-25 US US10/303,366 patent/US20030096795A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT199900111A (es) | (3s) tetrahidro-3-furanil (1s,2r)-3-[[(4-aminofenil) sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamatode calcio. | |
| DE60214179D1 (de) | IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN | |
| BR0114321A (pt) | Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto | |
| EA200500723A1 (ru) | Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита c, и связанных с ним заболеваний | |
| AP2003002915A0 (en) | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis. | |
| CO5050303A1 (es) | Composicion farmaceutica para tratar infecciones virales y metodos para su preparacion su aplicacion | |
| BR0209821A (pt) | Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos | |
| EA200300134A1 (ru) | Замещенные соединения тетрациклина (варианты), фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния субъекта | |
| BR0115447A (pt) | Inibidores de tripeptìdeo de hepatite c | |
| UY35542A (es) | Métodos y composiciones para tratar el virus de la hepatitis c | |
| ATE539744T1 (de) | Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem | |
| AR023388A1 (es) | INHIBIDORES DE aP2 DE BIFENILOS QUE CONTIENEN COMPUESTOS HETEROCICLICOS Y METODO DE TRATAMIENTO | |
| BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| BRPI0416283A (pt) | compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos | |
| ATE298741T1 (de) | Polyaromatische verbindungen zur behandlung von herpes-infektionen | |
| PT915898E (pt) | Forma i cristalina de claritromicina | |
| ATE450265T1 (de) | Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält | |
| BR0316771A (pt) | Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica | |
| BR0211118A (pt) | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal | |
| EA199700222A1 (ru) | Сульфонилалканоиламиногидроксиэтиламиносульфонамид в качестве ингибиторов ретровирусной протеазы | |
| DE69531944D1 (de) | Neue hiv-protease-inhibitoren | |
| ATE364043T1 (de) | Pyrazolo-pyridine für die behandlung von herpes- ansteckungen | |
| BR9408305A (pt) | Composto composição farmacêutica processos para tratamento de aids e da infecção por hiv para preparação da infecção por hiv e para inibição de protease de hiv e combinação de compostos | |
| DE69034226D1 (de) | Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu | |
| AR013193A1 (es) | Composicion limpiadora, composicion limpiadora para su uso como composicion suavizante de telas y uso de las mismas. |